MedTech Innovator

RevBio is commercializing an injectable, self-setting, osteoconductive bone adhesive biomaterial that can bond bone to bone and bone to metal in a wet field environment. The company's showcase product, Tetranite, is being reviewed by the FDA for a growing body of applications including oral, craniofacial, orthopedic, and neurosurgical indications. Over time, this synthetic adhesive biodegrades and is replaced by new bone. This unique material will reduce the duration and complexity of medical procedures, allow for more minimally invasive surgeries, and will improve patient outcomes by reducing recovery time and the overall cost of care.

At CloudMedx, we collect and convert disparate healthcare data into a holistic, actionable view of the individual. Our aligned approached is based on integrating with existing systems, becoming an intuitive extension of the way providers, payers, and even patients collaborate. CloudMedx’s mission was born out of the near-death experience of the founder’s father as a result of a misdiagnosis. This was ultimately a symptom of an overrun system that does not function as well as it could. In order to deliver better, more accurate care, we decided to take an aligned approach; to unite healthcare across the continuum and benefit both patients, payers, and doctors. By using data as our superpower instead of an obstacle, together we can fundamentally change the future of healthcare.

Bright Uro is an early-stage medical technology company. It is building the next generation of diagnostic devices for Urology. Utilizing advanced hardware, software, and data science can unlock new data streams and offer actionable insight for clinicians.

Gravitas Medical is a developer personalized automated nutrition management system for hospital nutrition. The company was founded in 2015 and is headquartered in San Francisco, California.

TrackX Technology develops a tracking technology that provides real-time virtual live fluoroscopy. It focuses on creating profound procedurally driven imaging solutions that provide priceless benefits to the surgeon, hospital, and entire operating room.

Garwood Medical Devices is a developer of electronic medical devices intended to eliminate infection-causing bacteria on metallic implants without the need for follow-up surgeries, while also allowing patients to retain their implants, enabling medical practitioners to treat implant infections in a better and more effective manner.

MeaCor develops novel transcatheter devices for the treatment of heart disease.

MicroGEM serves to democratize molecular biology by moving molecular techniques out of skilled laboratories to non-laboratory settings.

Cari Health develops remote medication monitors that allow clinicians to prescribe medications and receive real-time reporting on medication levels. Its monitors are wireless sensors that are worn on the patient's skin and continuously send data about medication levels to the cloud. The company was founded in 2015, incorporated in 2021 and is headquartered in San Diego, California.

Augment Health is developing a noninvasive bladder monitor and AI algorithm for 7M patients with bladder dysfunction following neurologic disease or injury, a $12.3B market. The technology shifts in-clinic diagnostics, which today face a 44% inconclusive test rate, to the home while also eliminating reversed bladder filling and rectal catheterization through proprietary data analysis.

Fluid Biomed is a medical device start-up focused on creating an implantable dissolving stent for the treatment of brain aneurysms. Founded by neurosurgeons, the company aims to improve patient outcomes by providing a device that promotes healing while minimizing the need for invasive procedures.

Tricog Health offers cardiac diagnostic tools to help solve cardiovascular conditions by identifying them in real-time and with accuracy. Tricog's medical-grade AI and intuitive tools improve the cardiac care of patients by solving cardiac care infrastructure, expertise, bandwidth, availability, and efficiency gaps. Tricog is committed to providing virtual cardiac diagnostic tools and services to all healthcare providers, assisting them in making accurate, timely, and consistent diagnoses and providing timely care.

52 North Health aims to improve healthcare with a medical device that uses artificial intelligence (AI) to determine the risk of neutropenic sepsis for patients undergoing chemotherapy.

Healthcare X.0 is an online healthcare platform that provides its clients with digitization solutions. The platform provides its clients with health, vascular, patient, onco, nephro, cardio, wound, tele, patient, and diabetic assist database solutions. Healthcare X.0 was launched in 2013 by and is based in Niedersachsen.

Phiex Technologies on-demand, interactive materials for efficient and cost-effective medical device manufacturing, food safety and packaging, and innovations for pathogens.

MindMics is an emerging wearable company revolutionizing the information they can understand about the inner workings of our bodies and health. They hears every heartbeat to capture clinically meaningful biometrics accurately within real-time to unleash mental performance.

ABO holds an exclusive license from Northwestern University and Evanston Northwestern Healthcare to multiple pending patents.

Altratech Limited designs biosensors and semiconductor chips for DNA testing of food traceability for agri business. The company was incorporated in 2013 and is based in Shannon, Ireland.

At Avelas Biosciences, their mission is to advance a new standard-of-care in cancer surgery by providing a real time luminous map for oncologic surgeons, leading to improved surgical results and better outcome for patients.

Subtle Medical is a healthcare technology company that provides AI-powered medical imaging. Its products, SubtlePET and SubtleMR, are FDA Cleared and CE Marked AI product that enhances images in PET and MR exams aimed for faster & safer workflow. The company's SubtleGAD technology is also awarded by RSNA and a $1.6M NIH SBIR Grant to facilitate the adoption using AI to make imaging exams safer. They provide a vendor-agnostic AI infrastructure powering its products and providing service and analytics to clinical imaging providers. Subtle Medical's goal is to improve the quality, value, and accessibility of medical imaging by significantly reducing cost, imaging time, and radiation dose.

ThermopeutiX offers imaginative, innovative, and economical solutions. They provide therapeutic solutions for vascular-related disorders and other issues.

Orbit Genomics technology platform enables early disease detection, treatment, and prevention of complex diseases. The platform analyzes repetitive DNA which uniquely reflects both inherited and acquired disease risk. They provides technology platform analyzes a different part of your DNA that uniquely reflects both inherited predisposition to disease.

Bone Health Technologies is a Redwood City-based health-tech company developing innovative, non-invasive, and science-backed solutions for people with low bone density. Its flagship product, Osteoboost, is an FDA-cleared wearable medical device clinically proven to significantly slow the loss of bone density and bone strength through patented precision vibration therapy in postmenopausal women with osteopenia. Inspired by NASA-funded research and driven by science and a commitment to improving health outcomes, Osteoboost is poised to become the new standard of care – offering a convenient, non-pharmacological, pain-free treatment to the nearly 64 million Americans at risk of osteoporotic fractures.

Koya Medical is a transformative healthcare company developing breakthrough treatments for lymphedema and venous diseases to increase movement, mobility, and personalized care that is unavailable with traditional compression therapy.

Venari Medical’s mission focus is on the innovation of unparalleled safe, effective, patient-centered medical devices that improve quality of life for those with debilitating vascular disease. Venari Medical are developing BioVena™ - a more effective, less invasive, and faster treatment for all venous disease patients. It is uniquely positioned to disrupt current treatment practices which have seen only medium level innovation in the past decade. The team is based at Ireland's medtech cluster in Galway. Only 1.3 million of the 120 million people in the US & EU who suffer from venous disease currently receive endovenous treatment each year. 3 million venous ulcer patients are completely unserved, using ineffective compression bandaging. Venari Medical offers an unrivaled lower risk and unparalleled effective non-thermal treatment which will allow more patients who suffer from Venous Disease to access effective treatment. The indication for the use of superficial venous ablation is also set to widen to treat venous ulcers that currently incur annual costs of $33Bn to insurers in the US & EU. The Venari Medical technology can be used as a safe and effective treatment for the whole spectrum of Venous Disease from varicose veins to active venous ulcers.

Pristine Surgical has developed a first-of-its-kind, single-use visualization platform for surgical and diagnostic rigid endoscopic procedures by combining state-of-the-art, high-definition digital imaging with advanced LED lighting, artificial intelligence and cloud-based software. Its single-use arthroscopes and laparoscopes are delivered in a 100% sterile kit, and together with its cloud-based workflow reduction software, promises to reduce cost, reduce risk and increase efficiency for over 23 million procedures per year.

CoapTech is an early-stage medical device company aiming to improve medical care delivery for patients young and old around the world. The company seeks to bring a series of breakthrough medical devices to worldwide markets, leveraging a patent-pending, disruptive technology called Coaptive Ultrasound which is owned by the company. Its devices reduce healthcare costs and improve safety, quality, patient experience, and access to services around the globe. Invented by Dr. Tropello, CoapTech delivers a novel platform technology combining magnetic attraction for device placement guidance, and low-cost, point-of-care ultrasound for visual feedback in diagnostic, interventional, and therapeutic procedures. Strong rare-earth magnets are used to manually guide devices placed inside the human body, while real-time, low-cost ultrasound provides visual feedback to the clinician to ensure safety. This platform technology, invented by the company founder, has the potential to disrupt multiple medical procedures, substantially reducing costs while improving safety and patient experience. Their lead use case, selected because of its low risk, clear FDA pathway, and strong commercial viability, is for the insertion of gastrostomy tubes. They have defined the use of Coaptive Ultrasound to perform this novel gastrostomy procedure, as Percutaneous Ultrasound Gastrostomy (PUG). Briefly, PUG is a point-of-care (as opposed to the operating room) procedure for inserting gastrostomy tubes which can be quickly and easily performed by non-surgical providers. It employs readily available medical devices such as ultrasound, feeding tubes, guide wires, and dilators.

The company provides digital health software and hardware intended to offer proprietary insights into the pulmonary vasculature non-invasively and the product pipeline aims to address both at-home monitoring and critical care applications in categories such as heart failure and hemodynamics.

Conavi Medical is a technique for visualizing the intracardiac and intravascular systems that is intended to direct minimally invasive procedures. The company's technology makes use of a catheter-based ultrasound system that can produce 2-D and 3-D ultrasound images of cardiac anatomy all the way around the catheter's tip, allowing medical professionals to perform cardiovascular procedures like ablations that might need access to specific areas of the heart.

Medable provides a global decentralized trial platform that streamlines design, recruitment, retention, and data quality, replacing siloed systems with integrated digital tools, data, and interfaces to accelerate trial execution. The platform connects patients, sites, and clinical trial teams to improve patient access, experience, and outcomes. It is now used by leading biopharma sponsors and clinical research organizations worldwide and has been used for trials in 30+ countries and 26 languages. It was founded in 2015 and is headquartered in Palo Alto, California.

Spire Health specializes in continuous respiration sensing and high-adherence, patient-friendly ambulatory monitoring. Its mission is to harness the power of algorithms and sensors to improve health outcomes by empowering patients and physicians with useful and actionable data.

ODS Medical Inc. is a medical device company that seeks to commercialize their exclusive Raman spectroscopy system for real-time detection of tissue abnormalities through the development, manufacture and sales of products for a range of clinical settings. ODS Medical Inc. is dedicated to bringing to the hands of physicians the next generation of diagnostic tools. Building on our revolutionary proprietary platform technology, we integrate cutting edge optical probes with the most sophisticated software, based on machine learning algorithms, to empower doctors to make critical decisions- in real-time - with unprecedented sensitivity, specificity and accuracy.

The future of infectious disease diagnostics starts at Day Zero. By using whole-genome sequencing (WGS) and our proprietary enabling technologies, Day Zero is creating a new class of sequencing-based in-vitro diagnostics that generates clinically actionable data at scale. Our technologies include novel sample preparation methods enabling unprecedented ultra-high enrichment of pathogen DNA for sequencing directly from clinical samples, machine learning algorithms that provide clinically actionable diagnostic results, and a world-class database of WGS and drug efficacy profiles. Day Zero Diagnostics is on a mission to transform the way infectious disease diagnostics are performed by generating the stream of real-time sequencing data required to change how we track, manage and combat infectious diseases. With an enormous unmet clinical and economic need, we are targeting bloodstream infections and sepsis for our first application. The life expectancy of a patient with septic shock is 24 hours without fast effective antibiotic treatment. However, even when successful, current diagnostics take 2-5 days to identify the pathogen AND provide its antibiotic susceptibility profile. The lack of rapid, accurate, and comprehensive diagnostics, forces physicians to “carpet bomb” patients with severe infections with powerful, yet toxic, broad-spectrum antibiotics, which is not only ineffective in many cases but can also lead to significant morbidity and mortality. Day Zero delivers a complete diagnosis, including both the species and antibiotic resistance profile, in hours vs. days, enabling the physician to use a targeted treatment on day zero of hospital admission and resulting in better patient outcomes and cost savings.

PharmaJet is a user-friendly, inexpensive device for fluid injection into the body without a needle. Able to compete with traditional needle-syringe delivery, which inherently poses costly needle-stick, re-use, and pass-along disease risk, the technology creates a positive ROI back for every injection. Unique in the field of jet injection because of its ability to reach all target tissues (IM, SC--0.5 mL, and ID--0.1 mL) accurately and comfortably, supported by wide regulatory claims (global and country-specific) PharmaJet's platforms are the only commercially available devices that effectively address the 3 B annual immunization market. It was founded in 2005 and headquartered in Golden, Colorado.

The Otricath™ introduces a new perspective on therapy delivery. The platform technology delivers cancer-fighting agents to solid tumors with unparalleled control, predictability, and safety for optimal therapeutic benefit and minimal systemic toxicity.

Nebula Industries is solving the problem of medical adhesive related injuries for those with fragile skin, particularly older people, using innovative approaches developed at MIT/Brigham and Women's Hospital.

OncoTAb, Inc., a North Carolina based startup, was co-founded by Mayo Clinic alumna Dr. Pinku Mukherjee, with a mission to improve the quality of cancer care by addressing unmet cancer diagnostic and therapeutic needs. The company’s first product, Agkura™ Personal Score, is a simple, non-invasive blood test offered as a supplement to mammography for women with dense breast tissue. Mammograms fail to detect cancer in 50% of women with high breast tissue density*, resulting in late stage diagnosis and mortality. The Agkura™ Personal Score shows a continuous trend of increasing values from benign disease through Breast Cancer Stages 1 to 4, with statistically significant increases prior to late stage breast cancer. Women with dense breast tissue can bi-annually monitor their personalized score in conjunction with annual mammograms. An increasing trend would indicate the need for additional imaging modalities and result in earlier stage diagnosis of breast cancer.

M&S Biotics is a healthcare Internet of Things (IoT) company focused on improving a surgical procedure's efficiency, efficacy, and safety by implementing their Biotic Integration system. This company was born out of necessity to put patient care first while alleviating the strain healthcare institutions face rising costs, limited resources, and an uncertain regulatory landscape. The Biotic Integration system leverages our proprietary Radio-Frequency Identification (RFID) technology and artificial intelligence to automate surgical counting in the operating room while providing real-time data analytics concerning instrument utilization. Combined, this can lead to millions of dollars in costs savings while affording the ability to perform more surgeries per year driving revenue growth for hospitals.

Encellin develops a novel thin-film cell encapsulation device for cell-based therapeutics. It has dedicated experts focused on the investigation and advancement of next-generation therapies. It aims to help patients with chronic diseases, starting with Type 1 diabetes. It was founded in 2016 and is headquartered in San Francisco, California.

Revolutionary Medical Devices, Inc. began June 2014 where it received critical acclaim at the Post-Graduate Assembly (PGA) for Anesthesiology. RMD has received worldwide recognition from Key Opinion Leaders in Anesthesia and its technologies are living up to their name, “Revolutionary”. The company’s mission is to utilize current clinical literature to drive the development of innovative technologies to optimize patient positioning during airway management and anesthesia. RMD develops airway management products to significantly improve anesthesiologist workload, O.R. turnover time, and easier patient intubation.

ITGI Medical is a bio-medical engineering company specializing in research and development, design, manufacture and distribution of high quality heterologous tissue covered stents for Cardiovascular and Neurovascular interventions. Their focus is on current technologies and applications that improve the standard of care for patients around the world in the fields of interventional Cardiology and Interventional Neuro-Radiology for the application in Coronary and neurological aneurysms, treatment of Fistulas, Saphenous Vein Graft occlusion (SVG Disease) and vascular perforations. Studies conducted prove that ITGI’s propriety technology can address these clinical problems in a safe and effective manner.

Enspectra Health, based in Mountain View, California, has developed the world’s first hand-held multiphoton imager for human use and is delivering imaging systems to researchers investigating the structure and function of muscle, tendon, cartilage, skin, and other tissues.

AVA Health Technologies is building a disruptive software platform that addresses challenges in pediatric care for children with acute, chronic, and rare conditions Our vision is to fill the gap in funding and focus in dedicated pediatric research and to provide a collaborative ecosystem for care that can facilitate discovery of new cures.

Genetesis is a rapidly growing medical technology company redefining the way patients with a risk of myocardial ischemia and coronary artery disease are clinically diagnosed, monitored and screened.

Nanowear is a developer of a nanosensor technology used to be applicable in a broad array of medical conditions and chronic disease states. Its proprietary technology allows transmission of real-time data wirelessly through a wearable fabric that provides medical professionals with accurate and continuous diagnostic data that is cost-effective and unobtrusive. Nanowear was founded in 2014 and is headquartered in New York.

Avenda Health has built a multi-modal AI decision support platform to bring superhuman abilities to cancer surgeons and oncologists power the future of cancer care. Our FDA-cleared inference engine, Unfold AI, build synthetic spatial maps of cancer incorporating the totality of a patient's diagnostic data (imaging, pathology, biomarkers, clinical information) and reveals invisible tumor extent to guide patients and their physicians to improve clinical decision making and outcomes.

Abreos Biosciences develops lateral flow assays that measure the activity of high-value biologics. Its simple devices can be used for quality assurance, pharmacokinetic monitoring, and authentication in field, forensic, or point of care settings. We deliver value by enhancing brand protection, improving patients’ outcomes, and enabling rapid authentication for counterfeit prevention and end-user confidence. The company was founded in 2013 and headquartered in San Diego, California.

Centerline Biomedical, Inc. was founded in November 2014 and is based on technology developed at the Cleveland Clinic. Centerline's mission is to develop advanced navigation systems that initially target interventional vascular procedures.

Green Sun Medical is developing a dynamic spinal alignment brace to help treat conditions like Scoliosis and Kyphosis. The company's brace applies continuous corrective pressure to the spine and helps in the treatment of spinal deformities such as kyphosis and adolescent scoliosis, enabling scoliosis patients to recover rapidly. Their tech-enabled dynamic brace will provide precise corrective pressure to patients. Green Sun Medical was founded in 2015 and is headquartered in Fort Collins, CO.

Adient’s mission is the development of absorbable medical devices with the premise that implants should be safe and efficacious during their useful lifetime, and then simply vanish without intervention, alleviating costly removal procedures and downstream complications.

PreDxion Bio is an early-stage healthcare company revolutionizing testing and treatment through low-cost, user-friendly at-home diagnostics. Enabled by PreDxion’s proprietary multiplexed localized surface plasmon resonance (LSPR) technology, our first product is a rapid, saliva-based test for COVID-19, flu, pneumonia, common cold, and other respiratory diseases.

Spry health provides health care payers with real-time analytics to manage chronically ill patients, avoid preventable hospitalizations, and save money on the 5% of patients who drive 50% of health spending.

Linear Health Sciences is a medical device company creating products for various types of medical tubing based on its proprietary, breakaway safety-valve technology. This platform technology is designed to improve the healthcare experience for patients, caregivers, and healthcare facilities. The company has made substantial progress toward global patent protections and FDA clearance for the Orchid Safety Release Valve. There is a total addressable market of more than $1 billion annually for devices made by the company, which was founded by a physician and two engineers.

Adient’s mission is the development of absorbable medical devices with the premise that implants should be safe and efficacious during their useful lifetime, and then simply vanish without intervention, alleviating costly removal procedures and downstream complications.

Disease Diagnostic Group (DDG) is a pre-revenue medical device company specializing in the development of rapid, accurate, and inexpensive disease diagnostic tests.

MiNDERA Dx conducts research and development on non-invasive molecular testing for skin cancer and other skin diseases. The company is currently focused on a technology solution to extract skin biomarkers in a non-invasive manner. It was founded in 2013 and is based in San Francisco, United States.

Adult Medical Predictive Devices, Diagnostics and Displays, Inc. (AMP3D) has developed a platform for analytics and displays that makes sense of “Big Data” in health care. AMP3D at a glance enables earlier intervention and better outcomes by predicting potentially catastrophic events like emergent intubation, hemorrhage, and severe sepsis that can quadruple mortality and increase lengths-of-stay by more 9 days on average. AMP3D will use demonstrable return-on-investment to sell its platform as a service on a value-based pricing basis, aimed directly at quality measures and performance standards that impact reimbursement and payment. A 20% reduction in emergent intubations at a single medical ICU, for example, can save $600,000 annually; the addressable overall market opportunity for the in-patient market alone is in the billions of dollars.

Vixiar Medical develops non-invasive, cost-effective devices, and systems for monitoring cardiopulmonary diseases, particularly those with a significant clinical and economic burden. The Company’s first product, Indicor, is a handheld point of care device and digital platform for monitoring worsening heart failure.

Aperture Biomedical is a team of physicians and engineers working to improve vascular access for hemodialysis. As part of the Stanford Biodesign fellowship in medtech innovation, they identified a huge unmet clinical need: the two million people on dialysis depend on a sustainable method to access their blood supply. The life expectancy of an incidence dialysis patient is over five years but the current methods of access last less than a year, leading to expensive repairs and complications related to access management. To solve this need, their team designed a novel therapy to extend the patency of access and reduce downstream complications.

Swift Health Systems is a stealth stage medical device company developing INBRACE: a revolutionary, easy to use, wide indication, personalized orthodontic system hidden behind the teeth. Our patented self-guiding technology uses light and continuous forces to gently correct your smile with less pain and fewer doctor visits. INBRACE is FDA registered and a catalyst for disruption in orthodontics. INBRACE increases the number of people who will seek orthodontic treatment by addressing the top concerns for patients while driving practice growth for clinicians. Our platform leverages digital treatment planning, computer modeling, and direct digital manufacturing to create a scalable, patient customized solution that delivers the standard of care across the entire range of orthodontic cases.

Our journey began with a research project to develop a portable blood cell testing device for astronauts on space missions. Today, we are bringing that cutting-edge technology down to Earth to transform point-of-care diagnostics, from hospitals and clinics to pharmacies and home care. After nine years of development, CytoChip’s first product, CitoCBC®, is ready for launch. Using just one drop of blood, CitoCBC® delivers lab-quality CBC results within minutes, offering accuracy comparable to central laboratory analyzers at the point of care. At our core, we are a team of passionate engineers and scientists spanning two continents, united by a singular goal: to make reliable, affordable diagnostics accessible to more people worldwide. Our headquarters and R&D centerare located in California, USA, while our engineering and manufacturing center is based in Suzhou, China. We collaborate closely with leading U.S. hospitals to advance clinical validation and innovation. Starting with the world’s first CLIA Waived cartridge-based CBC, we are committed to tackling the toughest innovation challenges in point-of-care testing. Our mission is to empower healthcare providers with reliable, cost-effective diagnostics and make data-driven testing more accessible to patients and consumers.

Surgisense specializes in the design, development, testing, manufacturing, and marketing of innovative new technologies for medical devices. We focus on developing the next generation of “smart” sensing surgical instruments and medical devices to further enhance surgery, patient care, and patient safety.

Fibralign Corporation utilizes Nanoweave® a proprietary scaffolding technology to develop advanced biomedical devices. Fibralign has launched its first product, the BioBridge® Collagen Matrix, and is now engaging in clinical studies to evaluate its use for treating and preventing secondary lymphedema, as well as advancing R&D development for new applications for treating ischemia and novel delivery devices for use with stem cells and gene therapy.

ChemoFilter is developing a novel catheter device enables chemotherapy delivery in a targeted manner, reducing patient side effects and improving treatment efficacy. The ChemoFilter device filters chemotherapeutics from the bloodstream, preventing toxic drugs from leaving the tumor site. ChemoFilter’s first version will treat unresectable liver cancer, the 3rd leading cause of cancer death with over 600,000 new cases per year by working in tandem with trans-arterial chemoembolization (TACE), the current standard of care for this disease. ChemoFilter will save the healthcare system over $5,000 per patient, while increasing hospital and physician margins and improving patient care. ChemoFilter has potential worldwide sales of over $1 billion in liver cancer with the opportunity to expand into other cancers. A UCSF based startup, ChemoFilter is supported by seed grants from UCSF, Society of Interventional Radiology, and the prestigious NIH Small Business Technology Transfer (STTR) grant.

Tampa Medical Innovations, Inc. (TaMI) is a Medical Device company working on an innovative portfolio of products. Thsy have partnered with some of the leading Clinical and Academic institutions in the country to commercialize their “untapped” Medical Devices. Their business model is to focus on simple Class I and II devices that are low cost, have large market potential and will monetize quickly for their investors.

BrainStem Biometrics is on a mission to reduce risks and extend the lives of elderly critical care patients who many times leave the ICU in worse shape than when they arrived, in part to sedative mis-management. Their firm was established to address the global problem of over-sedation in critical care which costs health systems billions of dollars each year in unnecessary costs and inefficiencies. Furthermore, sub-optimal sedation has been shown to reduce the risks of 180-day mortality for ventilated critically ill patients and has been shown to prolong the duration of ventilation by an estimated 25-40% with associated costs and inefficiencies. They also expect that the mis-management of sedation results in significant increased reliance upon post-ICU healthcare and commensurate cost burdens.

NeuroTronik, spun out of medical technology incubator Synecor, is developing a medical device that could take the place of drugs currently used to heart failure. Read more about the company's technology,

At Hemova Medical, we seek innovative solutions towards vascular access. A patient's access is their lifeline, and currently available options inadequately address the need for a safe, reliable and robust means for hemodialysis administration

Silver Medical is dedicated to improving sports safety by providing a simple, rapid, and easy-to-use method for detection of concussion.

Headquartered in Silicon Valley, NeuroSyntek Modeling & Manufacturing is rapidly emerging as a leader in the field of regenerative medicine, a group of biomedical approaches to clinical therapies that involve the use of stem cells to replace or regenerate human cells, tissues or organs to restore or establish normal function. NeuroSyntek is entering human trials on amyotrophic lateral sclerosis (ALS) with a uniquely powerful personalized medicine solution and is able to help with other diseases - such as stroke, brain trauma, Parkinson's, diabetes - to ophthalmology, orthopedic and cosmetic applications. Leveraging their semiconductor platform they bring major cost and automation benefits into stem cell therapy. NeuroSyntek technology allows for autologous mono-phenotype stem-cells cultures to be screened, grown and differentiated for transplantation without the risk of transformation into tumors. They enable this revolutionary approach through the use of their proprietary StemOptimizer platform and behavioral models. This powerful combination allows for unprecedented control over the cellular behavior, in vitro, for precise, automated and continuous cell culture monitoring and manipulation. The StemOptimizer is build around an advanced System-on-Chip architecture and their proprietary silicon extra-cellular sensor. This design allows for an adaptive, dynamically reconfigurable, and able to learn architecture that is the anchor for their aggressive and broad-based product roadmap. Their disruptive technology will help to optimize the massively inefficient $6 trillion healthcare market by dramatically driving down costs and providing effective solutions for stem-cell therapies. In Phase I of their product roadmap they are addressing the $30B+ stem cells market.